Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Samumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual Congress | ||
By: Nasdaq / GlobeNewswire - 20 Jun 2018 | Back to overview list |
|
Phase 2 data in osteoarthritis and preclinical data in tendinopathy and psoriasis demonstrated the emerging breadth of the Samumed pipeline in arthritis related diseases and in dermatology SAN DIEGO, June 20, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC presented one oral presentation and five posters highlighting recent clinical and preclinical data for two of the company’s investigational drugs, SM04690 for the treatment of knee osteoarthritis (OA), and SM04755 for the treatments of psoriasis and tendinopathy, at the European League Against Rheumatism (EULAR) 2018 Annual European Congress of Rheumatology, held in Amsterdam from June 13-16, 2018. Additionally, two analyses of randomized-controlled trials (RCTs) in knee OA examining the effects of intra-articular (IA) saline injections on patient responses were shown in separate posters. “The data we presented at the EULAR conference highlighted the variety of Samumed pipeline compounds being developed for arthritic diseases,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. Key clinical data presented in one oral presentation entitled, “Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results From a 52 Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel Intra-Articular, Wnt Pathway Inhibitor,” included:
Preclinical and clinical data on SM04690 as a potential knee OA treatment were presented in three posters entitled, “Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Wnt Pathway Inhibitor (SM04690) for Knee Osteoarthritis Treatment,” “Radiographic outcomes were associated with pain and function responses: Post-hoc analysis from a phase 2 study of a Wnt pathway inhibitor, SM04690, for knee osteoarthritis treatment,” and “SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models.” Key points included:
Key preclinical data on SM04755 for the treatments of tendinopathy and psoriasis presented in two posters entitled, “Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasis” and “Experimental tendinopathy treatment with SM04755, a topical small molecule inhibitor of the Wnt pathway” included:
Data from two analyses of RCTs were presented in two posters entitled, “Potential Nociceptive Pain Relief of Intra-Articular Saline Control in Clinical Trials of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Trials” and “Adjusting for the Intra-Articular Placebo Effect in Knee Osteoarthritis Therapies.” The data presented included the following point:
A copy of the presentation materials can be found in the Publications section of the Samumed website. About the European League Against Rheumatism (EULAR) The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems. About SM04690 SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease-modifying drug for osteoarthritis (DMOAD). Preclinical data suggested SM04690 has a dual mechanism of action with three specific effects on joint health – generation of articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=20 About SM04755 SM04755 is a small-molecule Wnt pathway inhibitor and is being developed as a potential topical therapeutic for tendinopathy. Preclinical data suggested that SM04755 may inhibit inflammation, reduce fibrosis, and increase tenocyte differentiation (tendon repair). Additional information on Samumed’s SM04755 tendinopathy program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=13 SM04755 is also being developed as a potential topical treatment for psoriasis. Preclinical data suggested SM04755 has the potential to attenuate inflammation, epidermal thickening, and fibrosis. Additional information on Samumed’s SM04755 psoriasis program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=11 About Samumed Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at https://www.samumed.com/pipeline/default.aspx Corporate Contact: Investor Contact: Media Contact: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |